Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 31, Issue 5, 2008, Pages 431-438

  Salem, Riad ^a,e   Parikh, Pankit ^a   Atassi, Bassel ^a   Lewandowski, Robert J ^a   Ryu, Robert K ^a   Sato, Kent T ^a   Gates, Vanessa L ^a   Ibrahim, Saad ^a   Mulcahy, Mary F ^a   Kulik, Laura ^b   Liu, David M ^c   Riaz, Ahsun ^a   Omary, Reed A ^a   Kennedy, Andrew S ^d  

^a Department of Medicine   (United States)

^b NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^c Inland Imaging   (United States)

^d Wake Radiology Oncology   (United States)

^e Interventional Oncology ^*  (United States)

Author keywords

Brachytherapy; Intra arterial brachytherapy; Radioembolization; SIR spheres; TheraSphere; Yttrium 90 microspheres

Indexed keywords

MACROSALB TC 99M; MICROSPHERE; SIEMENS E-CAM; THERASPHERE; UNCLASSIFIED DRUG; YTTRIUM 90; YTTRIUM 90 GLASS MICROSPHERE;

ADULT; AGED; ARTICLE; ATELECTASIS; DIAGNOSTIC IMAGING; DOSIMETRY; DRUG DISTRIBUTION; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; IMAGE ANALYSIS; IMAGE DISPLAY; LIVER CELL CARCINOMA; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; PLEURA EFFUSION; RADIATION PNEUMONIA; SCINTILLATION CAMERA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; HEPATIC ARTERY; HUMANS; INCIDENCE; LIVER NEOPLASMS; LUNG; MALE; MIDDLE AGED; RADIATION PNEUMONITIS; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TISSUE DISTRIBUTION; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 55249090678     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e318168ef65     Document Type: Article

References (31)

1. Monto A, Wright TL. The epidemiology and prevention of hepatocellular carcinoma. Semin Oncol. 2001;28:441-449.
2. El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36(5 suppl 1):S74-S83.
3. Sasson AR, Sigurdson ER. Surgical treatment of liver metastases. Semin Oncol. 2002;29:107-118.
4. Yan ZP, Lin G, Zhao HY, et al. An experimental study and clinical pilot trials on yttrium-90 glass microspheres through the hepatic artery for treatment of primary liver cancer. Cancer. 1993;72:3210-3215.
5. Tehranipour N, AL-Nahhas A, Canelo R, et al. Concordant F-18 FDG PET and Y-90 Bremsstrahlung scans depict selective delivery of Y-90-microspheres to liver tumors: confirmation with histopathology. Clin Nucl Med. 2007;32:371-374.
6. Salem R, Lewandowski RJ, Atassi B, et al. Treatment of unresectable hepatocellular carcinoma with use of 90Y microspheres (TheraSphere): safety, tumor response, and survival. J Vasc Interv Radiol. 2005;16:1627-1639.
7. Kulik L, Carr B, Mulcahy M, et al. Safety and efficacy of Y90 radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71-81.
8. Ho S, Lau WY, Leung TW, et al. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med. 1997;24:293-298.
9. Slauson DO, Hahn FF, Benjamin SA, et al. Inflammatory sequences in acute pulmonary radiation injury. Am J Pathol. 1976;82:549-572.
10. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90 yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys. 1995;33:919-924.
11. Martinez A, Goffinet D. Irradiation with external beam and interstitial radioactive implant as primary treatment for early carcinoma of the breast. Surg Gynecol Obstet. 1981;152:285-290.
12. Graham MV, Purdy JA, Emami B, et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys. 1999;45:323-329.
13. Claude L, Perol D, Ginestet C, et al. A prospective study on radiation pneumonitis following conformal radiation therapy in non-small-cell lung cancer: clinical and dosimetric factors analysis. Radiother Oncol. 2004;71:175-181.
14. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341-1346.
15. Salem R, Thurston KG, Can BI, et al. Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol. 2002;13:S223-S229.
16. Lewandowski RJ, Sato KT, Atassi B, et al. Radioembolization with (90)Y microspheres: angiographic and technical considerations. Cardiovasc Intervent Radiol. 2007;30:571-592.
17. TheraSphere Yttrium-90 microspheres package insert, MDS Nordion, Kanata, Canada, 2004.
18. Salem R, Thurston KG. Radioembolizarion with 90 Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: Technical and methodologic considerations. J Vasc Interv Radiol. 2006;17:1251-1278.
19. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007;68:13-23.
20. Burton MA, Gray BN. Adjuvant internal radiation therapy in a model of colorectal cancer-derived hepatic metastases. Br J Cancer. 1995;71:322-325.
21. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
22. Lin M. Radiation pneumonitis caused by yttrium-90 microspheres: radiologic findings. AJR Am J Roentgenol. 1994;162:1300-1302.
23. Lau WY, Leung WT, Ho S, et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer. 1994;70:994-999.
24. Lau WY, Ho SK, Yu SC, et al. Salvage surgery following downstaging of unresectable hepatocellular carcinoma. Ann Surg. 2004;240:299-305.
25. Wong CY, Savin M, Sherpa KM, et al. Regional yttrium-90 microsphere treatment of surgically unresectable and chemotherapy-refractory metastatic liver carcinoma. Cancer Biother Radiopharm. 2006;21:305-313.
26. Ho S, Lau WY, Leung TW, et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med. 1996;23:947-952.
27. SIR-Spheres Yttrium-90 microspheres package insert, SIRTeX Medical, Lane Cove, Australia, 2004.
28. Dancey JE, Shepherd FA, Paul K, et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y-microspheres. J Nucl Med. 2000;41:1673-1681.
29. Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol. 1997;44:17-22.
30. Seppenwoolde Y, Lebesque JV, de Jaeger K, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys. 2003;55:724-735.
31. Avila-Rodriguez MA, Sehvyn RG, Hampel JA, et al. Positron-emitting resin microspheres as surrogates of (90)Y SIR-spheres: a radiolabeling and stability study. Nucl Med Biol. 2007;34:585-590.